Elixinol share price edges higher on half year earnings release

The Elixinol share price has edged 3% higher today after the company released its half year financial results. We take a closer look.

| More on:
range of hemp oil and skin products representing elixinol share price

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Elixinol Global Ltd (ASX: EXL) share price surged 6.25% higher to 17 cents today after the company released its half year financial results. This was followed by a slight pullback in the Elixinol share price which is currently trading at 16.5 cents at the time of writing.

Elixinol operates in the hemp-derived, also known as cannabidiol or CBD, industry. The company's major businesses are located in Australia, Europe, the United Kingdom and the United States.

What's moving the Elixinol share price?

Investors were driving the Elixinol share price higher this morning despite the company reporting that revenues from continuing operations came in at $7.9 million for the six months to June 2020. This was a sharp 51% decline on revenues in the first half of FY 2019. The impact of the coronavirus pandemic was particularly hard for the company in the US retail market.

There has been a transition during the six month period to Elixinol branded products that have a much higher operating margin. The latter now constitute 64% of overall revenues, compared to only 50% in the prior corresponding half.

Operating expenses for Elixinol declined by 12% to $19.6 million for the six month period. Meanwhile, adjusted earnings before interest, taxes, depreciation and amortisation (EBITDA) came in at $14.8 million compared to an EBITDA loss of $11 million in the prior corresponding period.

Elixinol ended 30 June with a relatively solid balance sheet. It had $16.8 million of cash and almost no debt on its books. The company also has a significant amount of existing inventory to support its growth strategy for more than a year.

Market outlook

While not providing any specific revenue guidance, Elixinol Global has highlighted some positive market trends already evident during FY 2021.

Executive Director and Group CEO, Oliver Horn, commented:

Post period, in July, we've seen the business improving across all divisions. All business units achieved internal EBITDA forecasts, demonstrating that revenue and cost have been well managed. 

With the European and UK business having secured extended distribution, an encouraging order book and launch of our new Elixinol Skin range, we are seeing a positive continuation of this trend in August. We have not yet realised full benefit from our cost reduction program – this will positively impact the business from H2 FY2020. 

Following its slight pull back, the Elixinol share price is now trading 3.1% up so far today. The company has had a challenging year to date with the Elixinol share price falling 67% in 2020. 

Motley Fool contributor Phil Harpur has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

A cute little kid in a suit pulls a shocked face as he talks on his smartphone.
Share Market News

Telstra share price hits 8-year high amid a lacklustre trading week

The ASX 200 communications services sector was the best performer last week, rising 2.96%.

Read more »

share buyers, investors, happy investors
ETFs

How I would build a $100,000 portfolio with ASX ETFs today

You don't need more than three ETFs to build a diversified portfolio...

Read more »

A young man pointing up looking amazed, indicating a surging share price movement for an ASX company
Broker Notes

These ASX 200 shares could rise 20% to 100%

Analysts are expecting these shares to deliver big returns over the next 12 months.

Read more »

Three people in a corporate office pour over a tablet, ready to invest.
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

The silhouettes of ten people holding hands with their arms raised against the sky, as the sun rises or sets in the background.
Share Gainers

Here are the top 10 ASX 200 shares today

ASX shares finished the trading week on a high this Friday.

Read more »

A businessman stacks building blocks.
Technology Shares

6% gain! What's up with Block shares today?

Block shares are up more than 34% since 2 May.

Read more »

Broker looking at the share price.
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A young man punches the air in delight as he reacts to great news on his mobile phone.
Share Gainers

Why ARB, Block, Mayne Pharma, and Paladin Energy shares are charging higher today

These shares are having a strong finish to the week. But why?

Read more »